-

04:22:37 PM

ATHA Stock News

ATHA - Athira Pharma Inc

06/22/22 7:00 AM

Nasdaq : ATHA

clinical trial

Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together showed potential diminished effect of fosgonimeton A pre-specified subgroup analysis of patients on

RHEA-AI

neutral

06/07/22 7:00 AM

Nasdaq : ATHA

management

Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the formation of a Scientific Advisory Board (SAB)

RHEA-AI

neutral

05/19/22 12:06 PM

Nasdaq : ATHA

Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced, based on the preliminary vote count provided by its

RHEA-AI

very positive

05/16/22 4:49 PM

Nasdaq : ATHA

Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical

RHEA-AI

very positive

05/16/22 8:00 AM

Nasdaq : ATHA

management

Ric Kayne Suspends Campaign to Elect Himself and George Bickerstaff to Athira Pharma Board of Directors

Richard A. Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc., today issued the following letter to Athira shareholders. I started my campaign for change at Athira Pharma, Inc. in February 2022, nominating myself and George Bickerstaff, to the Athira Board of Directors...

RHEA-AI

neutral

05/16/22 7:00 AM

Nasdaq : ATHA

clinical trial

Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and

RHEA-AI

neutral

05/12/22 4:05 PM

Nasdaq : ATHA

earnings

Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and

RHEA-AI

very positive

05/12/22 8:00 AM

Nasdaq : ATHA

Ric Kayne Issues Letter to Athira Shareholders Highlighting Need for Immediate Change to Athira Board

Richard A. Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc., today issued a letter to Athira shareholders outlining numerous, value-destructive missteps by the current Board of Directors, and detailing why immediate change to the Board at the 2022 annual meeting of...

RHEA-AI

neutral

05/11/22 4:15 PM

Nasdaq : ATHA

Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage

RHEA-AI

neutral

05/09/22 7:00 AM

Nasdaq : ATHA

clinical trial

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next